¹⁸F-AlF-NOTA-奥曲肽PET/CT在高级别G3神经内分泌肿瘤及神经内分泌癌中的诊断效能及与¹⁸F-FDG PET/CT的互补性
该研究回顾性分析了42例组织学证实的高级别神经内分泌肿瘤(28例G3 NET和14例NEC)患者,评估¹⁸F-AlF-OC PET/CT的诊断效能及其与¹⁸F-FDG PET/CT的互补性。结果显示¹⁸F-AlF-OC PET/CT患者层面检出率为92.9%,病灶层面检出率80.7%高于¹⁸F-FDG的72.9%,双示踪剂联合检出率提升至89.1%。结论支持¹⁸F-AlF-OC PET/CT在高级别NENs中具有高检出率,并可能指导PRRT准入。
要点
- ¹⁸F-AlF-OC PET/CT在高级别NENs患者中检出率达92.9%。
- 病灶层面¹⁸F-AlF-OC检出率80.7%高于¹⁸F-FDG的72.9%。
- 双示踪剂联合检出率89.1%,优于任一单药。
核心结论
- ¹⁸F-AlF-OC PET/CT在高级别NENs患者中表现出高检出率,相当比例患者呈强SSTR表达且全部病灶阳性,支持其指导PRRT准入的潜在作用。
- ¹⁸F-AlF-OC与¹⁸F-FDG PET/CT具有互补性,双示踪剂成像可提高整体诊断准确性。
研究设计与样本
- 回顾性分析2023年1月至2024年10月间426例接受¹⁸F-AlF-OC PET/CT的患者中42例组织学证实的高级别NENs(28例G3 NET和14例NEC)。
- 其中36例同时接受了¹⁸F-FDG PET/CT;病灶摄取超过器官本底且无法用生理分布解释判为阳性,摄取高于正常肝脏判为高摄取。
主要发现
- 患者层面¹⁸F-AlF-OC PET/CT阳性39/42例,检出率92.9%;28例(66.7%)呈高摄取,19例(45.2%)全部病灶阳性。
- 同时接受双扫描的36例中,¹⁸F-AlF-OC检出率91.7%(33/36),¹⁸F-FDG检出率88.9%(32/36)。
- 11例(30.6%)存在¹⁸F-AlF-OC阴性/¹⁸F-FDG阳性病灶,13例(36.1%)存在¹⁸F-AlF-OC阳性/¹⁸F-FDG阴性病灶。
- 病灶层面¹⁸F-AlF-OC检出率80.7%(547/678)高于¹⁸F-FDG的72.9%(494/678);¹⁸F-AlF-OC检出109个¹⁸F-FDG遗漏病灶,¹⁸F-FDG检出56个¹⁸F-AlF-OC遗漏病灶。
- 双示踪剂联合检出率89.1%(604/678),超过任一单药。
临床怎么用
- 在高级别NENs患者中可考虑使用¹⁸F-AlF-OC PET/CT评估SSTR表达,高摄取和全部病灶阳性特征可能支持PRRT患者筛选。
- 对于高级别NENs,¹⁸F-AlF-OC与¹⁸F-FDG双示踪剂PET/CT联合应用可提高病灶检出率,减少遗漏。
局限性
- 本研究为单中心回顾性分析,样本量有限(42例),需前瞻性大样本研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Radiolabeled somatostatin receptor (SSTR) analogues are widely utilized for both imaging (PET or scintigraphy) and peptide receptor radionuclide therapy (PRRT) in the management of neuroendocrine neoplasms (NENs). These approaches have been extensively validated in low- to intermediate-grade gastroenteropancreatic neuroendocrine tumors (NET G1 - G2). However, data on the use of SSTR imaging - particularly SSTR PET imaging - in patients with high-grade NETs (G3) and neuroendocrine carcinomas (NECs) remain limited. This study aimed to evaluate the diagnostic performance of ¹⁸F-AlF-NOTA-octreotide (¹⁸F-AlF-OC) PET/CT in patients with high-grade NENs and assess its complementarity with ¹⁸F-FDG PET/CT. METHODS: Out of 426 patients who underwent ¹⁸F-AlF-OC PET/CT between January 2023 and October 2024, 42 patients with histologically confirmed high-grade NENs (28 with G3 NETs and 14 with NECs) were retrospectively analyzed. 36 patients also underwent 18F-FDG PET/CT. Lesions were classified as positive on PET/CT if their uptake exceeded organ background activity and could not be explained by physiologic biodistribution. Tumor uptake higher than normal liver was considered high uptake. RESULTS: On a per-patient basis, ¹⁸F-AlF-OC PET/CT was positive in 39 of 42 patients, yielding a detection rate of 92.9%. Among all patients, 28 (66.7%, 28/42) exhibited high ¹⁸F-AlF-OC uptake, and 19 (45.2%, 19/42) demonstrated positivity in all lesions. Of the 36 patients who underwent both scans, detection rates were 91.7% (33/36) for ¹⁸F-AlF-OC and 88.9% (32/36) for ¹⁸F-FDG PET/CT. Discordant findings were observed in 11 patients (30.6%) with¹⁸F-AlF-OC-negative/¹⁸F-FDG-positive lesions and in 13 patients (36.1%) with ¹⁸F-AlF-OC-positive/¹⁸F-FDG-negative lesions. On a per-lesion basis, ¹⁸F-AlF-OC PET/CT showed a higher detection rate than ¹⁸F-FDG PET/CT (80.7% [547/678] vs. 72.9% [494/678]). Specifically, ¹⁸F-AlF-OC identified 109 lesions missed by ¹⁸F-FDG, while ¹⁸F-FDG identified 56 lesions missed by ¹⁸F-AlF-OC. The combined use of both tracers improved the detection rate to 89.1% (604/678), surpassing either modality alone. CONCLUSION: ¹⁸F-AlF-OC PET/CT demonstrated high detection rates in patients with high-grade NENs, with a substantial proportion showing strong SSTR expression and lesion-wide positivity, supporting its potential role in guiding PRRT eligibility. The complementary nature of ¹⁸F-AlF-OC and ¹⁸F-FDG PET/CT enhances overall diagnostic accuracy, making dual-tracer imaging a valuable approach in this setting.
引用
- Hou G, Jiang Y, Yang Y, et al. ¹⁸F-AlF-NOTA-octreotide PET/CT in high-grade G3 neuroendocrine tumors and neuroendocrine carcinomas: diagnostic performance and complementarity with ¹⁸F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2025. PMID: 41134321. doi:10.1007/s00259-025-07584-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。